Mural Oncology plc (NASDAQ:MURA – Get Free Report)’s share price traded down 1.9% during trading on Thursday . The stock traded as low as $3.44 and last traded at $3.53. 147,884 shares changed hands during trading, a decline of 44% from the average session volume of 262,671 shares. The stock had previously closed at $3.60.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley assumed coverage on Mural Oncology in a research report on Thursday, April 4th. They issued an “overweight” rating and a $13.00 price target on the stock.
View Our Latest Research Report on MURA
Mural Oncology Stock Down 1.9 %
Mural Oncology (NASDAQ:MURA – Get Free Report) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($3.57) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Mural Oncology plc will post -10.63 EPS for the current fiscal year.
About Mural Oncology
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
- Five stocks we like better than Mural Oncology
- Where to Find Earnings Call Transcripts
- Hasbro’s Management Made All the Right Calls This Quarter
- What is the Hang Seng index?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- 10 Best Airline Stocks to Buy
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
